Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Katie L. Kunze; Patrick W. Johnson; Noud van Helmond; Jonathon W. Senefeld; Molly M. Petersen; Stephen A. Klassen; Chad C. Wiggins; Allan M. Klompas; Katelyn A. Bruno; John R. Mills; Elitza S. Theel; Matthew R. Buras; Michael A. Golafshar; Matthew A. Sexton; Juan C. Diaz Soto; Sarah E. Baker; John R.A. Shepherd; Nicole C. Verdun; Peter Marks; Nigel S. Paneth; De Lisa Fairweather; R. Scott Wright; Camille M. van Buskirk; Jeffrey L. Winters; James R. Stubbs; Katherine A. Senese; Michaela C. Pletsch; Zachary A. Buchholtz; Robert F. Rea; Vitaly Herasevich; Emily R. Whelan; Andrew J. Clayburn; Kathryn F. Larson; Juan G. Ripoll; Kylie J. Andersen; Elizabeth R. Lesser; Matthew N.P. Vogt; Joshua J. Dennis; Riley J. Regimbal; Philippe R. Bauer; Janis E. Blair; Arturo Casadevall; Rickey E. Carter; Michael J. Joyner

doi:10.1038/s41467-021-25113-5

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Katie L. Kunze, Patrick W. Johnson, Noud van Helmond, Jonathon W. Senefeld, Molly M. Petersen, Stephen A. Klassen, Chad C. Wiggins, Allan M. Klompas, Katelyn A. Bruno, John R. Mills, Elitza S. Theel, Matthew R. Buras, Michael A. Golafshar, Matthew A. Sexton, Juan C. Diaz Soto, Sarah E. Baker, John R.A. Shepherd, Nicole C. Verdun, Peter Marks, Nigel S. PanethDe Lisa Fairweather, R. Scott Wright, Camille M. van Buskirk, Jeffrey L. Winters, James R. Stubbs, Katherine A. Senese, Michaela C. Pletsch, Zachary A. Buchholtz, Robert F. Rea, Vitaly Herasevich, Emily R. Whelan, Andrew J. Clayburn, Kathryn F. Larson, Juan G. Ripoll, Kylie J. Andersen, Elizabeth R. Lesser, Matthew N.P. Vogt, Joshua J. Dennis, Riley J. Regimbal, Philippe R. Bauer, Janis E. Blair, Arturo Casadevall, Rickey E. Carter, Michael J. Joyner

Research output: Contribution to journal › Article › peer-review

Abstract

Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.

Original language	English (US)
Article number	4864
Journal	Nature communications
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41467-021-25113-5
State	Published - Dec 1 2021

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-021-25113-5

Cite this

Kunze, K. L., Johnson, P. W., van Helmond, N., Senefeld, J. W., Petersen, M. M., Klassen, S. A., Wiggins, C. C., Klompas, A. M., Bruno, K. A., Mills, J. R., Theel, E. S., Buras, M. R., Golafshar, M. A., Sexton, M. A., Diaz Soto, J. C., Baker, S. E., Shepherd, J. R. A., Verdun, N. C., Marks, P., ... Joyner, M. J. (2021). Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nature communications, 12(1), Article 4864. https://doi.org/10.1038/s41467-021-25113-5

Kunze, KL, Johnson, PW, van Helmond, N, Senefeld, JW, Petersen, MM, Klassen, SA, Wiggins, CC, Klompas, AM, Bruno, KA, Mills, JR, Theel, ES, Buras, MR, Golafshar, MA, Sexton, MA, Diaz Soto, JC, Baker, SE, Shepherd, JRA, Verdun, NC, Marks, P, Paneth, NS, Fairweather, DL , Wright, RS, van Buskirk, CM, Winters, JL, Stubbs, JR, Senese, KA, Pletsch, MC, Buchholtz, ZA, Rea, RF, Herasevich, V, Whelan, ER, Clayburn, AJ, Larson, KF, Ripoll, JG, Andersen, KJ, Lesser, ER, Vogt, MNP, Dennis, JJ, Regimbal, RJ, Bauer, PR, Blair, JE, Casadevall, A, Carter, RE & Joyner, MJ 2021, 'Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors', Nature communications, vol. 12, no. 1, 4864. https://doi.org/10.1038/s41467-021-25113-5

@article{8922ed39044b479e9fba7d2d4f1e3e0b,

title = "Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors",

abstract = "Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.",

author = "Kunze, {Katie L.} and Johnson, {Patrick W.} and {van Helmond}, Noud and Senefeld, {Jonathon W.} and Petersen, {Molly M.} and Klassen, {Stephen A.} and Wiggins, {Chad C.} and Klompas, {Allan M.} and Bruno, {Katelyn A.} and Mills, {John R.} and Theel, {Elitza S.} and Buras, {Matthew R.} and Golafshar, {Michael A.} and Sexton, {Matthew A.} and {Diaz Soto}, {Juan C.} and Baker, {Sarah E.} and Shepherd, {John R.A.} and Verdun, {Nicole C.} and Peter Marks and Paneth, {Nigel S.} and Fairweather, {De Lisa} and Wright, {R. Scott} and {van Buskirk}, {Camille M.} and Winters, {Jeffrey L.} and Stubbs, {James R.} and Senese, {Katherine A.} and Pletsch, {Michaela C.} and Buchholtz, {Zachary A.} and Rea, {Robert F.} and Vitaly Herasevich and Whelan, {Emily R.} and Clayburn, {Andrew J.} and Larson, {Kathryn F.} and Ripoll, {Juan G.} and Andersen, {Kylie J.} and Lesser, {Elizabeth R.} and Vogt, {Matthew N.P.} and Dennis, {Joshua J.} and Regimbal, {Riley J.} and Bauer, {Philippe R.} and Blair, {Janis E.} and Arturo Casadevall and Carter, {Rickey E.} and Joyner, {Michael J.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

day = "1",

doi = "10.1038/s41467-021-25113-5",

language = "English (US)",

volume = "12",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

AU - Kunze, Katie L.

AU - Johnson, Patrick W.

AU - van Helmond, Noud

AU - Senefeld, Jonathon W.

AU - Petersen, Molly M.

AU - Klassen, Stephen A.

AU - Wiggins, Chad C.

AU - Klompas, Allan M.

AU - Bruno, Katelyn A.

AU - Mills, John R.

AU - Theel, Elitza S.

AU - Buras, Matthew R.

AU - Golafshar, Michael A.

AU - Sexton, Matthew A.

AU - Diaz Soto, Juan C.

AU - Baker, Sarah E.

AU - Shepherd, John R.A.

AU - Verdun, Nicole C.

AU - Marks, Peter

AU - Paneth, Nigel S.

AU - Fairweather, De Lisa

AU - Wright, R. Scott

AU - van Buskirk, Camille M.

AU - Winters, Jeffrey L.

AU - Stubbs, James R.

AU - Senese, Katherine A.

AU - Pletsch, Michaela C.

AU - Buchholtz, Zachary A.

AU - Rea, Robert F.

AU - Herasevich, Vitaly

AU - Whelan, Emily R.

AU - Clayburn, Andrew J.

AU - Larson, Kathryn F.

AU - Ripoll, Juan G.

AU - Andersen, Kylie J.

AU - Lesser, Elizabeth R.

AU - Vogt, Matthew N.P.

AU - Dennis, Joshua J.

AU - Regimbal, Riley J.

AU - Bauer, Philippe R.

AU - Blair, Janis E.

AU - Casadevall, Arturo

AU - Carter, Rickey E.

AU - Joyner, Michael J.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.

AB - Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.

UR - http://www.scopus.com/inward/record.url?scp=85112250457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112250457&partnerID=8YFLogxK

U2 - 10.1038/s41467-021-25113-5

DO - 10.1038/s41467-021-25113-5

M3 - Article

C2 - 34381030

AN - SCOPUS:85112250457

SN - 2041-1723

VL - 12

JO - Nature communications

JF - Nature communications

IS - 1

M1 - 4864

ER -

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this